Article Sidebar

Submitted
6 January 2022
Accepted
4 March 2022
Published
7 March 2022
Download
PDF
Statistic
Read Counter : 611 Download : 361

Main Article Content

Abstract

Highlights:

  1. Neutrophil to lymphocyte ratio (NLR) has been reported by several studies for its role as a biomarker in various diseases, however, the role of NLR in testicular GCT is still unclear.
  2. The characteristics and responses of testicular GCT patients among Indonesian men show similarity to other reports worldwide.
  3. As a parameter, NLR shows promise to be used as a potential biomarker for prognosis in testicular GCT.


Abstract:

The global incidence of testicular cancer is 1-2% from all cancers. The attempts to maintain high therapeutic rates while decreasing the treatment-related side effects and toxicity have become the current concern. However, the reports regarding testicular germ cell tumors (GCT) in Indonesia are limited. Thus, we aimed to evaluate the clinical characteristics of testicular GCT patients undergoing bleomycin, etoposide, and cisplatin (BEP) chemotherapy, as well as their chemotherapy response and side effects. We reported the data of patients with Testicular Germ Cell Tumor from January 2015 to December 2019. Several data were retrieved, including patient demographics, tumor characteristics, treatment, and prognosis outcome. A total of 67 patients with testicular germ cell tumors were included in this study. The mean age was 28.9 years old. The chemotherapy regimens used were four cycles of (BEP) in 36 patients (53.7%), followed by three cycles of BEP in 22 patients (32.8%). Patients with seminoma GCT mostly had a complete response (54.1%), whereas most patients with non-seminoma GCT had progressive disease (47.8%). The multiple logistic regression analysis showed that NLR and S staging were independently associated with the patient’s response to chemotherapy (OR 2.14, 95% CI 1.22, 3.78, p <0.01,OR 9.43, 95% CI 1.81, 49.14, p < 0.01). The clinical characteristics and response of testicular GCT patients among Indonesian men showed similarity with the current worldwide data. The NLR could be used as a potential biomarker for prognosis.

Keywords

Testicular cancer germ cell tumour BEP chemotherapy cancer

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite
Saputra, H. M., & Hakim, L. (2022). The Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR) in Testicular Germ Cell Tumor (GCT). Folia Medica Indonesiana, 58(1), 39–45. https://doi.org/10.20473/fmi.v58i1.32599
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Albers P, Albrecht W, Algaba F, et al (2015). Guidelines on testicular cancer: 2015 update. European Urology 68, 1054–1068.
  2. Baroni T, Arato I, Mancuso F, et al (2019). On the origin of testicular germ cell tumors: from Gonocytes to testicular cancer. Frontiers in Endocrinology 10, 1-8.
  3. Batool A, Karimi N, Wu X-N, et al (2019). Testicular germ cell tumor: A comprehensive review. Cellular and Molecular Life Sciences 76, 1713–1727.
  4. Bogefors C, Isaksson S, Bobjer J, et al (2017). Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome. Andrology 5, 711-717.
  5. Chae S, Kang KM, Kim HJ, et al (2018). Neutrophil–lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. Current Oncology 25, 113–119.
  6. Efstathiou E, Logothetis CJ (2006). Review of late complications of treatment and late relapse in testicular cancer. Journal of the National Comprehensive Cancer Network 4, 1059–1070.
  7. Farmanfarma KK, Mahdavifar N, Mohammadian-Hafshejani A, et al (2018). Testicular cancer in the world: An epidemiological review. J Canc Res 5, 1–5.
  8. Ferlay J, Shin H-R, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 127, 2893-2917.
  9. Fridlender ZG, Albelda SM (2012). Tumor-associated neutrophils: friend or foe?. Carcinogenesis 33, 949–955.
  10. Gaddam SJ, Chesnut GT (2021). Testicle cancer. StatPearls Publishing, Treasure Island.
  11. Ghazarian AA, Kelly SP, Altekruse SF, et al (2017). Future of testicular germ cell tumor incidence in the United States: Forecast through 2026. Cancer 123, 2320–2328.
  12. Gooden MJM, de Bock GH, Leffers N, et al (2011). The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. British journal of cancer 105, 93–103.
  13. Grivennikov SI, Greten FR, Karin M (2010). Immunity, inflammation, and cancer. Cell 140, 883–899.
  14. Hirahara T, Arigami T, Yanagita S, et al (2019). Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer 19, 1–7.
  15. den Hollander MW, Westerink N-DL, Lubberts S, et al (2016). Bleomycin-induced pulmonary changes on restaging computed tomography scans in two thirdsof testicular cancer patients show no correlation with fibrosis markers. The Oncologist 21, 995-1001.
  16. Howard R, Gilbert E, Lynch CF, et al (2008). Risk of leukemia among survivors of testicular cancer: A population-based study of 42,722 patients. Annals of Epidemiology 18, 416–421.
  17. Huddart RA, Norman A, Shahidi M, et al (2003). Cardiovascular disease as a long-term complication of treatment for testicular cancer. Journal of Clinical Oncology 21, 1513-1523.
  18. Ilktac, A. et al. (2020). The relationship of neutrophil to lymphocyte ratio with testicular cancer. International Braz J Urol 46, 101–107.
  19. Karakaya S, Karadag I, Ates O, et al (2021). Can neutrophil-to-lymphocyte ratiso or platelet-to-lymphocyte ratio predict chemotherapy response in testicular cancer?. Eurasian Journal of Medicine and Investigation 5, 269-273.
  20. Kusler KA, Poynter JN (2018). International testicular cancer incidence rates in children, adolescents and young adults. Cancer Epidemiology 56, 106–111.
  21. Lauritsen JE, Hansen MK, Bandak M, et al (2020). Cardiovascular risk factors and diesease after male germ cell cancer. Journal of Clinical Oncology 38, 584-592.
  22. Lavanderos MA, Cayun JP, Roco A, et al (2019). Association study among candidate genetic polymorphisms and chemotherapy-related severe toxicity in testicular cancer patients. Frontiers in Pharmacology 10, 1-10.
  23. Li X, Dai D, Chen B, et al (2018). The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. Journal of Cancer 9, 861–871.
  24. Miyamoto R, Inagawa S, Sano N, et al (2018). The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients. European Journal of Surgical Oncology 44, 607–612.
  25. Mjaess G, Chebel R, Karam A, et al (2021). Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in urological tumors: an umbrella review of evidence from systematic reviews and meta-analyses. Acta Oncologica 60, 704–713.
  26. Nistal M, Paniagua R, Gonzalez-Peramato P, et al (2016). Perspectives in pediatric pathology, chapter 25. Testicular and paratesticular tumors in the pediatric age group. Pediatric and Developmental Pathology 19, 471–492.
  27. Ohno Y (2019). Role of systemic inflammatory response markers in urological malignancy. International Journal of Urology 26, 31–47.
  28. Park JS, Kim J, Elghiaty A, et al (2018). Recent global trends in testicular cancer incidence and mortality. Medicine 97, 1-7.
  29. Prabawa IPY, Bhargah A, Liwang F, et al (2019). Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a predictive value of hematological markers in cervical cancer. Asian Pacific Journal of Cancer Prevention 20, 863–868.
  30. Purdue MP, Chen J, Devesa SS, et al (2005). International patterns and trends in testis cancer incidence. International Journal of Cancer 115, 822–827.
  31. Ribnikar D, Stukalin I, Bedard PL, et al (2021). The prognostic value of neutrophil-to-lymphocyte ratio in metastatic testicular cancer. Current Oncology 28, 107–114.
  32. Semaan A, Haddad FG, Eid R, et al (2019). Immunotherapy: Last bullet in platinum refractory germ cell testicular cancer. Future Oncology 15, 533–541.
  33. Steliarova-Foucher E, Colombet M, Ries LAG, et al (2017). International incidence of childhood cancer, 2001–10: A population-based registry study. Lancet Oncology 18, 719–731.
  34. Tan YG, Sia J, Huang HH, et al (2019). Neutrophil-to-lymphocyte ratio independently predicts advanced pathological staging and poorer survival outcomes in testicular cancer. Investigative and Clinical Urology 60, 176–183.
  35. Yin X, Wu L, Yang H, et al (2019). Prognostic significance of neutrophil–lymphocyte ratio (NLR) in patients with ovarian cancer: A systematic review and meta-analysis. Medicine 98, 1-6.
  36. Zhang J, Zhang H-Y, Li J, et al (2017). The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: A systematic review and meta-analysis. Oncotarget 8, 68837-68846.